

Specialty Guideline Management Oxervate

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Oxervate	cenegermin-bkbj

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications¹

Oxervate is indicated for the treatment of neurotrophic keratitis.

All other indications are considered experimental/investigational and not medically necessary.

Prescriber Specialties

This medication must be prescribed by or in consultation with an ophthalmologist or optometrist.

Oxervate SGM 2869-A P2024_R.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Coverage Criteria

Neurotrophic Keratitis¹⁻³

Authorization of 16 weeks (8 weeks total therapy per eye) may be granted for treatment of stage 2 and stage 3 neurotrophic keratitis when all of the following criteria are met:

- The member must experience persistent epithelial defects (PED) or corneal ulceration of at least 2 weeks duration refractory to one or more conventional non-surgical treatments (e.g., preservative free artificial tears).
- There is evidence of decreased corneal sensitivity (e.g., cotton swab method, Cochet-Bonnet contact aesthesiometer, CRCERT-Belmonte non-contact aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.
- The member has not received a previous 8-week course of Oxervate in the affected eye.

References

- 1. Oxervate [package insert]. San Mateo, CA: Dompe U.S. Inc.; December 2024.
- 2. Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Opthalmol. 2018;125(9):1332-1343. doi: 10.1016/j.ophtha.2018.02.022
- 3. Cunha AN, Bunya VY, Woodward MA, et al. Neurotrophic keratitis. American Academy of Ophthalmology EyeWiki. Updated June 18, 2024. Accessed October 9, 2024. https://eyewiki.aao.org/Neurotrophic_Keratitis.

Oxervate SGM 2869-A P2024_R.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.